LIU Jing, SHEN Jiajun, SONG Yan, LIU Yu, MA Chengbin, ZHANG Wenying.Value of pre-treatment β-hCG changes for predicting outcome of methotrexate treatment in patients with ectopic pregnancies[J].Journal of Tongji University(Medical Science),2024,45(5):735-739. [点击复制]
Value of pre-treatment β-hCG changes for predicting outcome of methotrexate treatment in patients with ectopic pregnancies
LIU Jing, SHEN Jiajun, SONG Yan, LIU Yu, MA Chengbin, ZHANG Wenying
((Department of Gynecology, Changning Maternity and Infant Health Hospital, Shanghai 200051, China))
Abstract:
Objective To investigate the value of pre-treatment β-hCG changes in predicting the outcome of methotrexate(MTX) treatment in patients with ectopic pregnancy(EP). Methods Clinical data of 114 patients with EP treated by single-dose MTX injection in Shanghai Changning Maternity and Infant Health Hospital were retrospectively analyzed. According to the outcomes of MTX treatment, 114 patients were classified into success group and failure group. The influencing factors of MTX treatment outcomes were analyzed. The efficacy of pre-treatment β-hCG changes for predicting MTX treatment outcome was evaluated with ROC curve. Results Among 114 EP patients treated with MTX, there were 69 cases in success group and 45 cases in failue group. The proportion of patients with decreased β-hCG before treatment in the success group(46/69, 66.7%) was significantly higher than that in the failure group(14/45, 31.1%, P=0.000). The ratio of serum β-hCG decrease before treatment(RBT) in the success group was significantly greater than that of the failure group(P=0.001). ROC analysis showed that the area under the curve(AUC) of RBT in predicting sussessful treatment outcome was 0.766, and the cut-off value was -6.5%, with a sensitivity and specificity of 84.4% and 60.9%, respectively. Conclusion For EP patients treated by single-dose MTX injection, the treatment outcome is significantly associated with pre-treatment β-hCG changes, and the ratio of serum β-hCG change before treatment(RBT) may be used as a predictor for treatment success in EP patients treated by single-dose MTX.